Guardant Health, Inc. announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant's Shield test. This agreement was facilitated through Hikma Pharmaceuticals PLC, Guardant's regional partner.
Colorectal cancer is the third most common cancer in Abu Dhabi, with 63% of cases diagnosed at a late stage. The introduction of the Shield blood test aims to significantly improve screening participation, early detection, and outcomes for the community.
The Shield test will be part of the ADPHC's IFHAS comprehensive health screening program, available at major healthcare facilities across Abu Dhabi, Al Ain, and Al Dhafra region. The program is expected to screen approximately 10,000 people in its first year, addressing low adherence rates due to its convenient blood-based approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.